Zacks Investment Research upgraded shares of Immuneering (NASDAQ:IMRX – Get Rating) from a hold rating to a buy rating in a research report report published on Wednesday, Zacks.com reports. The firm currently has $4.75 target price on the stock.
According to Zacks, “Immuneering Corporation is a biopharmaceutical company advancing a pipeline of oncology and neuroscience product candidates. The company’s product candidate includes IMM-1-104. Immuneering Corporation is based in CAMBRIDGE, Mass. “
Separately, Oppenheimer began coverage on shares of Immuneering in a report on Thursday, March 31st. They issued an outperform rating and a $25.00 price target for the company. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Immuneering presently has a consensus rating of Buy and a consensus price target of $29.13.
Immuneering (NASDAQ:IMRX – Get Rating) last issued its quarterly earnings results on Thursday, March 10th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.03). Immuneering had a negative net margin of 21.73% and a negative return on equity of 38.00%. The business had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.60 million. Equities research analysts expect that Immuneering will post -2.04 EPS for the current fiscal year.
In other news, Director Ann E. Berman acquired 6,000 shares of Immuneering stock in a transaction on Tuesday, March 15th. The stock was bought at an average cost of $6.40 per share, with a total value of $38,400.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have acquired 10,900 shares of company stock valued at $73,621 over the last ninety days.
Several hedge funds and other institutional investors have recently bought and sold shares of IMRX. New York State Common Retirement Fund purchased a new stake in shares of Immuneering in the third quarter worth approximately $45,000. Deutsche Bank AG purchased a new stake in shares of Immuneering in the third quarter worth approximately $126,000. TD Asset Management Inc. purchased a new stake in shares of Immuneering in the third quarter worth approximately $911,000. BlackRock Inc. purchased a new stake in shares of Immuneering in the third quarter worth approximately $40,472,000. Finally, Citigroup Inc. purchased a new stake in shares of Immuneering in the third quarter worth approximately $33,000. 47.41% of the stock is owned by institutional investors and hedge funds.
About Immuneering (Get Rating)
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors.
- Get a free copy of the StockNews.com research report on Immuneering (IMRX)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immuneering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuneering and related companies with MarketBeat.com's FREE daily email newsletter.